159341-91a 9fbd 8b 689a 4654d 12618c 205e 2b 0d -medium _jpg

In February 2014, Mitodys Therapeutics successfully raised £150,000 to fund the initial optimisation and validation of its drug-discovery platform through initial drug prototypes.

The Story

MitoDys is a drug-discovery platform, working on a novel approach to treating Parkinson’s disease.

MitoDys is headed up by founder Steven Zimmer and a world-class board of scientific and clinical advisors led by Dr David Weiner, a clinician scientist who is a noted expert in Parkinson’s disease, along with a network of academic laboratories and partner CROs.

The lead investor in this round was The Life Neurological Research Trust.

Mito Dys Theraputics Canvas

Where are they now?

We caught up with Mitodys at our event in April and found out about the company’s progress:

See current opportunities

Soshi Games

EIS
Media & Telecommunications
Soshi games, the innovative music application developer, has successfully raised £285k from angels and follow-on investors on SyndicateRoom.

No longer trading

Trading status

£9,500

Average investment

£285,000

Total raised

Radio Physics Solutions

EIS
Technology, Hardware & Equipment
Radio Physics Solutions, the company determined to make the world a safer place, has successfully raised £700k from a number of business angels and sophisticated investors on SyndicateRoom.

Active

Trading status

£17,949

Average investment

£700,000

Total raised

Bactest

EIS
Pharmaceuticals & Biotechnology
Bactest’s technology turns microbial activity into data, offering multiple industry applications. They raised £838,380.

No longer trading

Trading status

£13,478

Average investment

£930,000

Total raised

Canary

EIS
Technology, Hardware & Equipment
Canary is led by none other than Christopher Curry, co-founder of Acorn computers, William Cotton, former MD of Boots International, and Stuart Sheehy, previously at BUPA.

Active

Trading status

£10,458

Average investment

£251,000

Total raised

Mill Residential REIT

Property
First UK residential Real Estate Investment Trust (REIT), aiming to list on a UK stock exchange in December 2014.

Active

Trading status

£30,130

Average investment

£2,199,520

Total raised

Apta Biosciences

EIS
Pharmaceuticals & Biotechnology
Apta Biosciences – creators of a groundbreaking alternative to antibodies – came to SyndicateRoom for help closing their £1.55 million round. The spin-off from Japanese IT giant Fujitsu wound up breezing past their funding target, closing at an impressive £1,792,500.

Active

Trading status

£34,906

Average investment

£1,850,000

Total raised